Search for Clinical Trial Results

Dermatofibrosarcoma Protuberans - 19 Studies Found
Status | Study |
Completed |
Study Name: Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans Condition: Dermatofibrosarcoma Protuberans Date: 2005-10-20 Interventions: Drug: imatinib mesylate 400 mg orally twice a day for 10 - 14 days |
Completed |
Study Name: Imatinib in Dermatofibrosarcoma Protuberans (DFSP) Condition: Dermatofibrosarcoma Date: 2005-07-20 Interventions: Drug: Imatinib (Glivec) |
Terminated |
Study Name: Phase II Pazopanib Study in Advanced Dermatofibrosarcomas Condition: Dermatofibrosarcomas of DARIER FERRAND(DFSP) Date: 2010-01-28 Interventions: Drug: Pazopanib Administration of pazopanib per os 800mg/ qd during 6 months until stable response accor |
Completed |
Study Name: Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Condition:
Interventions: |
Completed |
Study Name: Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans Condition: Soft Tissue Neoplasms Date: 2005-09-12 |
Completed |
Study Name: Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Condition: Sarcoma Date: 2004-06-10 Interventions:
|
Completed |
Study Name: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Condition:
|
Completed |
Study Name: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Condition:
|
Completed |
Study Name: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Condition:
|
Completed |
Study Name: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Condition:
|